Exiting Covagen

How investors fared in takeout of mAb platform play Covagen by J&J

Terms of Johnson & Johnson's takeout of Covagen AG are undisclosed, but the antibody platform company's largest investor said the deal is likely one of the biggest this year in terms of both size and investor returns for private, venture-backed European biotechs.

Covagen is developing a pipeline of multi-specific FynomAbs, which are fusions of antibodies and Fynomers. Fynomers are small proteins derived from the SH3 domain of FYN proto-oncogene src family tyrosine kinase (FYN) that can

Read the full 751 word article

How to gain access

Continue reading with a
two-week free trial.